Keytruda’s reign continues; pharma’s megadeal drought
Keytruda’s reign continues; pharma’s megadeal drought
Keytruda’s reign continues; pharma’s megadeal drought
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.